The FDA vote is three weeks out — and the room has quietly changed

The honest read on peptides, hormones, and midlife — what the evidence supports, what it doesn't, and what's just good marketing.

The big FDA vote is now three weeks out — and the committee itself has changed

On July 23–24, the Pharmacy Compounding Advisory Committee reviews seven peptides (BPC-157, KPV, TB-500, MOTS-c on day one; DSIP, Semax, Epitalon on day two) and votes on whether they can be legally compounded again. As we covered last time: even a yes doesn't put anything on a shelf tomorrow — FDA rulemaking follows, typically 6 to 18 months out.

Here's the angle almost nobody's flagging. The committee that rejected every peptide in 2024 had thirteen members. Several were removed during 2025 and haven't been replaced, leaving only about four seated members going into this meeting — seated under an administration that has openly championed peptides. That's a very different room than the one that voted no two years ago, which is why close observers now think the odds of at least a partial "yes" are meaningfully higher.

Why we're flagging it rather than cheering it. Read honestly, this cuts both ways. A more favorable committee could restore regulated, quality-controlled access — genuinely better than the gray market, where independent testing recently found 37 of 37 sampled research-peptide products failed purity grades. But a vote that tracks the political wind rather than the evidence is exactly what skeptics worry about, because the human data on most of these compounds hasn't actually improved since they were last rejected. Better access and thin evidence can both be true at once. We'll report the actual votes when they land.

The number that reframes the whole peptide conversation

The gray-market peptide economy just crossed a $100 million annual run rate — and, tellingly, former illicit-drug-precursor manufacturers are now among the suppliers, while independent purity testing has collapsed. This is the real backdrop to the FDA hearing: the question isn't only "do these work," it's "if people are going to use them anyway, should there be a legal, tested supply instead of this?" A genuinely hard public-health tradeoff — and more interesting than the "miracle vs. snake oil" framing you'll see everywhere else.

The keeper concept: when someone points to the coming hearing as proof peptides "work," remember what's actually being voted on — legal access, not efficacy. A compound can be legal to compound and still have thin evidence behind it. Those are two separate questions, and almost all the marketing depends on you conflating them.

Hormone therapy just hit a milestone — and the nuance that matters is timing

New prescribing data shows estrogen-based HRT use among women 45–54 rose more than 180% in recent years — as of early 2026, about 1 in 20 women in that age group had an HRT prescription. After two decades of women being scared off hormones by the now heavily-reinterpreted 2002 WHI study, the pendulum is swinging back, helped by the FDA removing longstanding boxed warnings from certain hormone therapies.

But here's the nuance that actually matters for you — timing, and what "timing" really means. The benefits of HRT (symptom relief, and in the research, meaningfully lower cardiovascular and even dementia risk) tend to be greatest when started earlier — within about 10 years of menopause. One analysis of 50+ studies found Alzheimer's risk up to 32% lower in women who began HRT within five years of menopause. But it is never too late: starting later still helps, and helps more than not starting at all. The "window" isn't a door that closes — it's a gradient.

Which is the whole Peptune thesis, again. The headlines say "HRT is back." The honest version is "HRT, with a clinician who knows your history, is a genuinely powerful tool at any stage — and it's not right for everyone." That's less shareable and far more useful. Hormones are the floodlight, and no spotlight substitutes for getting the room lit first. If you're in perimenopause or early menopause, the timing of that conversation with your clinician may matter as much as the decision itself.

Educational, not medical advice. Always consult a qualified clinician before starting, stopping, or changing any treatment. Regulatory details current as of writing and subject to change.

← All issues